#Thinksabio latest news
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesityPreclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesityPreclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291